Literature DB >> 434676

Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.

R I Fisher, V T DeVita, S P Hubbard, R Simon, R C Young.   

Abstract

Thirty-two patients with Hodgkin's disease who relapsed after a first complete remission induced by nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) were retreated with MOPP chemotherapy. Nineteen patients achieved a second complete remission. Median duration of the second complete remission was 21 months. The likelihood of achieving a second complete response could be predicted by the duration of the first response. Fourteen of 15 patients whose first complete remission was longer than 12 months achieved a second complete response in contrast to five of 17 patients whose initial complete remission lasted less than 12 months (P less than 0.001). Median survival of all patients in this study who were re-treated with MOPP was longer than 4 years after their first relapse. We conclude that patients with Hodgkin's disease who relapse after a first complete remission induced by MOPP are not necessarily resistant to further MOPP therapy and can achieve long-term survival with MOPP reinduction.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434676     DOI: 10.7326/0003-4819-90-5-761

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  24 in total

1.  Hodgkin's Disease 1985.

Authors:  R E Myers; J S Ginsberg
Journal:  Can Fam Physician       Date:  1985-06       Impact factor: 3.275

2.  Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin.

Authors:  P Collard; P Weynants; C Francis; D O Rodenstein
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

Review 3.  Rechallenging with anthracyclines and taxanes in metastatic breast cancer.

Authors:  Carlo Palmieri; Jonathan Krell; Colin R James; Catherine Harper-Wynne; Vivek Misra; Susan Cleator; David Miles
Journal:  Nat Rev Clin Oncol       Date:  2010-08-31       Impact factor: 66.675

4.  Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.

Authors:  Bijay Nair; John D Shaughnessy; Yiming Zhou; Marie Astrid-Cartron; Pingping Qu; Frits van Rhee; Elias Anaissie; Yazan Alsayed; Sarah Waheed; Klaus Hollmig; Jackie Szymonifka; Nathan Petty; Antje Hoering; Bart Barlogie
Journal:  Blood       Date:  2009-04-23       Impact factor: 22.113

Review 5.  Refractory and relapsing Hodgkin's disease: role of high-dose chemotherapy with bone marrow transplantation.

Authors:  M Thomas; N Gattermann; W Schneider
Journal:  Klin Wochenschr       Date:  1990-06-05

6.  An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU.

Authors:  A L Lennard; P J Carey; G H Jackson; S J Proctor
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Current approaches to the treatment of advanced-stage Hodgkin's disease.

Authors:  J J Rusthoven
Journal:  CMAJ       Date:  1986-09-01       Impact factor: 8.262

Review 8.  Current management of Hodgkin's disease.

Authors:  B C Behrens; R C Young; V T DeVita
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 9.  [Modern pharmacotherapy of Hodgkin disease].

Authors:  A Josting; K Behringer; A Engert; V Diehl
Journal:  Internist (Berl)       Date:  2004-01       Impact factor: 0.743

10.  Phase-II trial with M-CAVe-CEC as a salvage chemotherapeutic regimen for early relapsed or primary refractory Hodgkin's disease.

Authors:  G Vreugdenhil; M Jongen-Lavrencic; J M Raemaekers; B E de Pauw
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.